1 suspended. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Suspended 1 |
| Phase 2 | 1 | Suspended 1 |
Follow Dfmo: new trials by email Literature Review of Dfmo trials Research Report on Dfmo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) Pembrolizumab, Difluoromethylornithine - Non Small Cell Lung Cancer, Lung Cancer | Phase 1 / Phase 2 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 45 | 2024-08-07 | 2026-03-06 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
H. Lee Moffitt Cancer Center and Research Institute (1)
United States (1)